cinaciguat

Cinaciguat is an experimental small molecule drug developed as a nitric oxide (NO)-independent activator of soluble guanylate cyclase (sGC). By binding to the haem-free or oxidized form of sGC, cinaciguat mimics the effect of NO and directly activates sGC, leading to increased production of cyclic GMP (cGMP) and resulting in vasodilation. This mechanism is particularly relevant in conditions where endogenous NO signaling is impaired. Cinaciguat has been investigated primarily for the treatment of acute decompensated heart failure, where it demonstrated hemodynamic benefits such as reduced pulmonary capillary wedge pressure and vascular resistance, but its development was hampered by dose-limiting hypotension[1][3][4][5][6]. The drug was developed by Bayer HealthCare.

Other names

cinaciguat